News

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction of a new manufacturing facility, the Virginia startup is well-positioned to transition its portfolio of proprietary active ingredients to end-to-end commercial production.

The agreement will bolster FMC’s capabilities in Lepidoptera control and AgroSpheres’ speed to market for its RNA portfolio. Throughout the collaboration, AgroSpheres’ internally generated RNA targets will be used to deliver a wide range of highly potent and selective biomodalities.

“In a global market desperately in need of effective tools to combat resistance, FMC has shown foresight by investing in next-generation technologies and setting aggressive goals to meet demand for high-performance biologicals,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “As leaders in bringing molecules to market, they are an ideal partner for AgroSpheres as we progress to comprehensive product development. We are excited to codevelop with the FMC team.”

“AgroSpheres’ scalable manufacturing and delivery technology got our attention, but once we took a closer look at their suite of proprietary actives, we saw significant value in a partnership,” said Dr. Seva Rostovtsev, Executive Vice President and Chief Technology Officer of FMC Corporation. “Integrating this technology into our world class insecticide portfolio will help diversify and complement our crop protection offerings.”

The technology and biomodality platform

RNA interference biomolecules have demonstrated great promise in the lab but have struggled to yield consistent results for commercial biological development. AgroSpheres’ patented AgriCell manufacturing technology offers the missing link with a highly scalable and cost-effective platform. AgriCell production of encapsulated biomolecules delivers enhanced stability, performance and targeted uptake in pests. AgroSpheres’ groundbreaking biomodality approach targets specific, yet diverse biological actions, efficiently multiplying product offerings and innovation.

“FMC is committed to finding sustainable and pollinator-friendly solutions for global insect control,” said Lisa Hoffman, PhD, Director of Development Biology and External Partnerships at FMC Corporation. “After an extensive review of RNA technologies, it was clear that AgroSpheres has the right capabilities to help us be successful in this space.”

Reese Blackwell, Chief Business Officer at AgroSpheres, underscored the company’s firm commitment to the rapid development of commercial biomodalities, aiming to provide growers with solutions that are both effective and environmentally friendly. He emphasized the need for next-generation products to address the challenges currently faced by biologicals to ensure broad farmer adoption.

“Like FMC, we aim to be at the forefront of biological input innovation,” said Blackwell. “Our development prioritizes efficacy, scalability and rapid market entry. Observing FMC’s impressive revenue generation from newly launched products over the past five years confirms that they are the perfect collaborator to expedite our pioneering technologies from the laboratory to the farm gate.”

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights